Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D
Top Cited Papers
- 1 May 2007
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (9), 4654-4663
- https://doi.org/10.1128/jvi.02696-06
Abstract
Recombinant adenovirus serotype 5 (rAd5) vector-based vaccines are currently being developed for both human immunodeficiency virus type 1 and other pathogens. The potential limitations associated with rAd5 vectors, however, have led to the construction of novel rAd vectors derived from rare Ad serotypes. Several rare serotype rAd vectors have already been described, but a detailed comparison of multiple rAd vectors from subgroups B and D has not previously been reported. Such a comparison is critical for selecting optimal rAd vectors for advancement into clinical trials. Here we describe the construction of three novel rAd vector systems from Ad26, Ad48, and Ad50. We report comparative seroprevalence and immunogenicity studies involving rAd11, rAd35, and rAd50 vectors from subgroup B; rAd26, rAd48, and rAd49 vectors from subgroup D; and rAd5 vectors from subgroup C. All six rAd vectors from subgroups B and D exhibited low seroprevalence in a cohort of 200 individuals from sub-Saharan Africa, and they elicited Gag-specific cellular immune responses in mice both with and without preexisting anti-Ad5 immunity. The rAd vectors from subgroup D were also evaluated using rhesus monkeys and were shown to be immunogenic after a single injection. The rAd26 vectors proved the most immunogenic among the rare serotype rAd vectors studied, although all rare serotype rAd vectors were still less potent than rAd5 vectors in the absence of anti-Ad5 immunity. These studies substantially expand the portfolio of rare serotype rAd vectors that may prove useful as vaccine vectors for the developing world.Keywords
This publication has 33 references indexed in Scilit:
- Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-ReactivityJournal of Virology, 2006
- Modulation of DNA Vaccine-Elicited CD8 + T-Lymphocyte Epitope Immunodominance HierarchiesJournal of Virology, 2006
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicityJournal of General Virology, 2006
- Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan AfricaJournal of Clinical Microbiology, 2006
- Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus MonkeysJournal of Virology, 2005
- Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman PrimatesJournal of Virology, 2005
- Neutralizing Antibodies and CD8 + T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine VectorsJournal of Virology, 2004
- Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy VectorsJournal of Clinical Microbiology, 2003
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003